SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
AstraZeneca PLC Release: Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared With 250 mg.1,2
Your Message